The analysis of tumor cells or tumor cell products obtained from blood or other body fluids
(“liquid biopsy”[LB]) provides a broad range of opportunities in the field of oncology. Clinical …

Liquid biopsies (LBs), particularly using circulating tumor DNA (ctDNA), are expected to
revolutionize precision oncology and blood-based cancer screening. Recent technological …

Simple Summary Early diagnosis of breast cancer greatly increases the chance of cure and
survival from the disease. The mammogram is widely used for early detection of breast …

RNA methylations, as the prevalent post-transcriptional modifications, are critical in
regulating various biological processes, such as RNA transcription, splicing, structure …

Lung, breast, colorectal, and prostate cancers are the most incident worldwide. Optimal
population-based cancer screening methods remain an unmet need, since cancer detection …

Cell-free DNA (cfDNA) is easily accessible in peripheral blood and can be used as
biomarkers for cancer diagnostics, prognostics, and therapeutics. The applications of cfDNA …

Breast cancer is one of the most frequent malignancies among women worldwide. Methods
for screening and diagnosis allow health care professionals to provide personalized …

Circulating tumor cells (CTCs) are rare tumor cells released from primary, metastatic, or
recurrent tumors in the peripheral blood of cancer patients. CTCs isolation from peripheral …

Breast cancer management has progressed immensely over the decades, but the disease is
still a major source of morbidity and mortality worldwide. Even with enhanced imaging …

Liquid biopsy, a minimally invasive approach, is a highly powerful clinical tool for the real‐
time follow‐up of cancer and overcomes many limitations of tissue biopsies. Epigenetic …